Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus

Summary

The purpose of this study is to examine the participant's preference for treatment with once-weekly dosing of DPP-4 inhibitor trelagliptin versus once-daily dosing of DPP-4 inhibitor alogliptin among the participants with type 2 diabetes mellitus who are being treated with once-daily dosing of DPP-4 inhibitor.

Timeline

Start

2017-08-18

Primary completion

2018-02-09

Completion

2018-02-09

Outcome

Met primary endpoint

paper After 16 weeks of treatment, 51.7% of patients preferred treatment with alogliptin compared with 30.0% selecting trelagliptin (p = .014); PMID 31366262 ↗

registry analysis (other test); Trelagliptin 100 mg + Alogliptin 25 mg vs Alogliptin 25 mg + Trelagliptin 100 mg; p = 0.0141; Mainland-Gart Test NCT03231709 ↗

Publications

• Meguro S, Matsui S, Itoh H. Treatment preference for weekly versus daily DPP-4 inhibitors in patients with type 2 diabetes mellitus: outcomes from the TRINITY trial. Curr Med Res Opin. 2019 Dec;35(12):2071-2078. doi: 10.1080/03007995.2019.1651130. Epub 2019 Aug 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alogliptin	Unknown	25 mg	Oral
Subject	Trelagliptin	Small molecule	100 mg	Oral

Indications